June 21, 2016
Mitsubishi Tanabe Pharma said on June 20 that it has filed a new drug application in the US for its amyotrophic lateral sclerosis (ALS) drug edaravone, which would mark the company’s stand-alone foray into the market, if approved. Edaravone, known...read more